ResMed Valuation Multiples

ResMed Overview

About ResMed

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Founded

1994

HQ

Employees

10.6K

Website

resmed.com

Sectors

Medical DevicesBioTechHealthTech

Financials (LTM)

Revenue: $6B

EBITDA: $2B

EV

$32B

Valuation Multiples

Multiples.vc

Start free trial

ResMed Financials

ResMed reported last 12-month revenue of $6B and EBITDA of $2B.

In the same LTM period, ResMed generated $3B in gross profit, $2B in EBITDA, and $2B in net income.

ResMed P&L

In the most recent fiscal year, ResMed reported revenue of $5B and EBITDA of $2B.

ResMed expects next 12-month revenue of XXX and NTM EBITDA of XXX

ResMed Stock Performance

ResMed has current market cap of $33B, and enterprise value of $32B.

ResMed's stock price is $22.42.

ResMed Valuation Multiples

ResMed trades at 5.8x EV/Revenue multiple, and 14.9x EV/EBITDA.

ResMed Financial Valuation Multiples

As of April 20, 2026, ResMed has market cap of $33B and EV of $32B.

Equity research analysts estimate ResMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

ResMed has a P/E ratio of 21.2x.

ResMed Margins & Growth Rates

ResMed's revenue in the last 12 month grew by 8%.

ResMed's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.

ResMed's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ResMed's rule of X is 61% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

ResMed Public Comps

See public comps and valuation multiples for other Medical Devices comps.

ResMed M&A Activity

ResMed acquired XXX companies to date.

Last acquisition by ResMed was on XXXXXXXX, XXXXX. ResMed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

ResMed Investment Activity

ResMed invested in XXX companies to date.

ResMed made its latest investment on XXXXXXXX, XXXXX. ResMed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).